Tofacitinib Citrate

枸橼酸托法替布

Report date: 2026/05/26 20:00:28
NMEFirst In Class

Base Information

Drug NameTofacitinib Citrate
Drug Alias Name托法替布托西替尼托法尼布托法替尼枸橼酸托法替尼 +[17] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK1 inhibitorsTyrosine-protein kinase JAK2 inhibitorsTyrosine-protein kinase JAK3 inhibitors
TargetsTyrosine-protein kinase JAK1Tyrosine-protein kinase JAK2Tyrosine-protein kinase JAK3
Therapy Area/IndicationsPlaque psoriasisRejection of renal transplantationCoronavirus Disease 2019 (COVID-19) +[47] 
Global Approved IndicationsArthritis, Rheumatoid
Approved Indications in ChinaArthritis, Rheumatoid
Original Approved Country/TerritoryUnited States
Original Approved Date2012/11/06
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[59] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity of Texas Southwestern Medical CenterOregon Health And Science UniversityWest Institute of Computing Technology +[22] 
Inactive CompaniesHanmi Pharmaceutical Co LtdGodecke GmbhWashington University School Of Medicine +[15] 
Active IndicationsPsoriasisVitiligoAlopecia Areata +[30] 
Inactive IndicationsPlaque psoriasisRejection of renal transplantationCoronavirus Disease 2019 (COVID-19) +[17] 

Other Information

ATC CodeL04AF01
Related LinksWikipediaDrugBankKEGG